Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors Hematology
Biosimilars
Global Health
Abbreviations
TabrectaⓇ - MET inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milestone(s)
Publication
NCT04427072 (CINC280A2301)
Non-small cell lung cancer
Phase 3
90
Progression free survival (PFS) per blinded independent review committee (BIRC)
using RECIST v1.1
Arm 1: 400mg of capmatinib tablets administered orally twice daily
Arm 2: Docetaxel 75 mg/m2 by intravenous infusion every 21 days
Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or
Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation
(MET?ex14).
Primary 2022
Final: 2024
TBD
NCT04816214 GEOMETRY-E (CINC280L12301)
Non-small cell lung cancer
Phase 3
245
Run-in part: Incidence of dose limiting toxicities (DLTs)
Randomized part: Progression free survival (PFS)
Arm 1: Experimental: Combination of capmatinib + osimertinib (run-in part).
Arm 2: Experimental: Combination of capmatinib + osimertinib (randomized part)
Arm 3: Active Comparator: platinum + pemetrexed based doublet chemotherapy
Adult subjects with Non-small Cell Lung cancers as second line therapy
Primary: 2025
Final: 2027
TBD
123 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation